The MSUCNs were modified with folic acid (FA) as a tumor-targeting ligand, Ce6 as a PS, and 1-methyl-tryptophan (1MT) as an indoleamine 2,3-dioxygenase (IDO) inhibitor. Here, IDO2 is linked to neoplasm.